0%

est. 2Y upside i

HealthcareSeries B

Debut is building the future of beauty with cutting-edge AI and biotechnology, creating high-performing, innovative ingredients and formulations that propel the industry forward. The company specializes in scientifically-discovered, clinically-proven and inherently sustainable ingredients that provide maximum efficacy.

Rank

#2944

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Due to missing valuation and revenue data, a quantitative upside estimate is impossible.

Last updated: July 3, 2026

Bull (20%)0%

Could capture high growth if partnerships scale and regulation clears, but unknown valuation prevents numeric upside.

Base (55%)0%

Gradual commercialization with ongoing competition from incumbents; upside indeterminate due to missing data.

Bear (25%)0%

Down round or failure to achieve regulatory approvals; preference stack implies near-total loss for common.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

0%

$126M total funding with no disclosed valuation; preference overhang could wipe out common if exit below $126M.

Dilution Risk

high

No revenue disclosed; likely need further funding within 2 years, diluting current equity pool.

Secondary Liquidity

none

No secondary market data available; pre-IPO liquidity unlikely in 2 years.

View all 3 open roles at Debut →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Debut's data — designed to show you've done your homework.

  • 1

    “How does Debut plan to compete with incumbents like BASF that are also investing in biotech ingredients?”

  • 2

    “Can you walk through the unit economics of an ingredient licensing deal and how revenue grows over a 2-year horizon?”

  • 3

    “What is your view on the current valuation and preference stack; how much common stock can I expect to retain after future dilutive rounds?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.